GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Sold by Bank of America Corp DE

Bank of America Corp DE reduced its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 64.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 149,697 shares of the company’s stock after selling 269,320 shares during the period. Bank of America Corp DE’s holdings in GoodRx were worth $696,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Clearbridge Investments LLC acquired a new stake in shares of GoodRx during the 4th quarter valued at about $5,863,000. Raymond James Financial Inc. acquired a new position in shares of GoodRx during the 4th quarter worth approximately $2,500,000. Vanguard Group Inc. boosted its holdings in shares of GoodRx by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 8,373,039 shares of the company’s stock worth $38,935,000 after purchasing an additional 460,753 shares during the last quarter. EVR Research LP purchased a new stake in shares of GoodRx during the 4th quarter valued at approximately $1,761,000. Finally, Dimensional Fund Advisors LP raised its position in shares of GoodRx by 22.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company’s stock valued at $9,264,000 after buying an additional 369,553 shares during the period. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Price Performance

Shares of NASDAQ:GDRX opened at $4.11 on Tuesday. The company has a 50-day simple moving average of $4.24 and a 200-day simple moving average of $4.53. GoodRx Holdings, Inc. has a one year low of $3.68 and a one year high of $9.26. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -137.00, a PEG ratio of 2.46 and a beta of 1.16.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.05. The firm had revenue of $202.97 million during the quarter, compared to analysts’ expectations of $202.25 million. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.08 earnings per share. On average, analysts predict that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

Insider Buying and Selling at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm’s stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $4.09, for a total transaction of $43,668.93. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.53% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on GDRX. Wells Fargo & Company reduced their price target on shares of GoodRx from $8.00 to $7.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 29th. UBS Group cut their price objective on GoodRx from $6.00 to $5.25 and set a “neutral” rating on the stock in a research report on Tuesday, May 13th. The Goldman Sachs Group lowered their target price on shares of GoodRx from $6.00 to $5.00 and set a “neutral” rating for the company in a research note on Friday, May 9th. Finally, Truist Financial decreased their price objective on shares of GoodRx from $6.50 to $5.50 and set a “hold” rating for the company in a research note on Thursday, April 10th. Five equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.55.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.